Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

LUDWIG Heinz ADAM Zdeněk HÁJEK Roman GREIL Richard TOTHOVÁ Elena KEIL Felix AUTZINGER Eva Maria THALER Josef GISSLINGER Heinz LANG Alois EGYED Miklós WOMASTEK Irene ZOJER Niklas

Year of publication 2010
Type Article in Periodical
Magazine / Source Journal of clinical oncology : official journal of the American Society of Clinical Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords multiple myeloma; renal failure
Description By intent-to-treat analysis a myeloma response was obtained in 72% of 18 previously and 50 not previously treated patients (complete response [CR]/near CR [nCR], 38%; very good partial response [VGPR], 15%; partial response [PR], 13%; minor response [MR], 6%). Renal response was achieved in 62% of patients (renal CR, 31%; renal PR, 7%; renal MR, 24%). Median GFR increased from 20.5 to 48.4 mL/min. GFR improvement correlated with tumor response; the greatest increase to 59.6 mL/min was seen in the group of patients with CR/nCR/VGPR. Median progression-free survival was 12.1 months. One- and 2-year survival rates were 72% and 58%, respectively. Survival did not differ between patients with and without renal response but was inferior in previously treated patients (P < .001). BDD induced a high rate of myeloma and renal responses, and treatment was well tolerated.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.